## Jacques Hm Cohen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9199027/publications.pdf

Version: 2024-02-01

623188 839053 21 986 14 18 citations g-index h-index papers 23 23 23 1228 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients. Immunobiology, 2021, 226, 152093.	0.8	15
2	Key role of the number of complement receptor $1$ on erythrocytes for binding of Escherichia coli to erythrocytes and for leukocyte phagocytosis and oxidative burst in human whole blood. Molecular Immunology, 2019, 114, 139-148.	1.0	3
3	Nanosized Fluorescent Diagnostic Probes Consisting of Single-domain Antibodies Conjugated with Quantum Dots. Materials Today: Proceedings, 2016, 3, 518-522.	0.9	O
4	Multiphoton Imaging of Tumor Biomarkers in situ Using Single-domain Antibodies Conjugated with Quantum Dots in a Set Orientation. Materials Today: Proceedings, 2016, 3, 523-526.	0.9	6
5	Detection of carcinoembryonic antigen using single-domain or full-size antibodies stained with quantum dot conjugates. Analytical Biochemistry, 2015, 478, 26-32.	1.1	24
6	Multiphoton imaging of tumor biomarkers with conjugates of single-domain antibodies and quantum dots. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1701-1709.	1.7	59
7	Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 516-525.	1.7	140
8	HLA-A29 and Birdshot Chorioretinopathy. Ocular Immunology and Inflammation, 2011, 19, 397-400.	1.0	57
9	Advanced procedures for labeling of antibodies with quantum dots. Analytical Biochemistry, 2011, 416, 180-185.	1.1	36
10	Semiconductor quantum dots for multiplexed bio-detection on solid-state microarrays. Critical Reviews in Oncology/Hematology, 2010, 74, 1-15.	2.0	53
11	Analysis of complement receptor Type 1 expression on red blood cells in negative phenotypes of the Knops blood group system, according to CR1 gene allotype polymorphisms. Transfusion, 2010, 50, 1435-1443.	0.8	12
12	Biocompatible fluorescent nanocrystals for immunolabeling of membrane proteins and cells. Analytical Biochemistry, 2004, 324, 60-67.	1.1	312
13	Functionalized nanocrystal-tagged fluorescent polymer beads: synthesis, physicochemical characterization, and immunolabeling application. Analytical Biochemistry, 2004, 334, 257-265.	1.1	77
14	The C3b/C4b receptor (CR1, CD35) on erythrocytes: methods for study of the polymorphisms. Molecular Immunology, 1999, 36, 819-825.	1.0	22
15	Catabolism of the human erythrocyte C3b/C4b receptor (CR1, CD35): vesiculation and/or proteolysis?. Immunopharmacology, 1997, 38, 129-140.	2.0	20
16	Immunostaining for membrane attack complex of complement is related to cell necrosis in fulminant and acute hepatitis. Gastroenterology, 1995, 108, 495-504.	0.6	22
17	Discordance in the determination of non- or low-responders to HBV vaccine using IMx-AUSAB® or AUSAB®-RIA. Vaccine, 1993, 11, 485.	1.7	O
18	Homogeneous phase pyrophosphate (PPi) measurement (H3PIM) A non-radioactive, quantitative detection system for nucleic acid specific hybridization methodologies including gene amplification. Journal of Immunological Methods, 1992, 156, 55-60.	0.6	81

#	Article	IF	CITATIONS
19	Human T lymphocytes expressing the C3b/C4b complement receptor type one (CR1, CD35) belong to FcÎ <sup>3</sup> receptor-positive CD4-positive T cells. Cellular Immunology, 1989, 121, 383-390.	1.4	17
20	Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. Aids, 1989, 3, 397-400.	1.0	29
21	Instantaneous roll-blot from cellulose acetate after electrophoresis. Journal of Immunological Methods, 1987, 104, 25-30.	0.6	0